Famvir (Famciclovir)
famciclovir 500 mg tablet, 56 · ORAL · PBS code 8896F
STREAMLINEDWhat it costs
AU$26.04 PBS-determined price per 56 units
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2006-04-01.
- • Repeats: 5.
- • PBS program: GE.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Recurrent moderate to severe genital herpes
Episodic treatment or suppressive therapy
Patient must be immunocompromised.
Microbiological confirmation of diagnosis [viral culture, antigen detection or nucleic acid amplification by polymerase chain reaction (PCR)] is desirable but need not delay treatment.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Recurrent moderate to severe oral or labial herpes
Episodic treatment
Patient must have HIV infection; AND
Patient must have a CD4 cell count of less than 500 million per litre.
Microbiological confirmation of diagnosis [viral culture, antigen detection or nucleic acid amplification by polymerase chain reaction (PCR)] is desirable but need not delay treatment.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Recurrent moderate to severe oral or labial herpes
Suppressive therapy
Patient must have HIV infection; AND
Patient must have CD4 cell counts of less than 150 million per litre.
Microbiological confirmation of diagnosis [viral culture, antigen detection or nucleic acid amplification by polymerase chain reaction (PCR)] is desirable but need not delay treatment.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Recurrent moderate to severe oral or labial herpes
Suppressive therapy
Patient must have HIV infection; AND
Patient must present with other opportunistic infections or AIDS defining tumours.
Microbiological confirmation of diagnosis [viral culture, antigen detection or nucleic acid amplification by polymerase chain reaction (PCR)] is desirable but need not delay treatment.
Sponsor: Clinect Pty Ltd ABN 76 150 558 473
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.